There are currently two authorized vaccines against herpes zoster (HZ) that have been shown to be safe and effective in its prevention: Zostavax, a zoster vaccine live (ZVL), and Shingrix, a recombinant zoster Vaccine (RZV). Because ophthalmologists work with vision-threatening complications of zoster, such as herpes zoster ophthalmicus (HZO), they are in a good position to advocate for vaccination. Our aim was to determine the current knowledge among Spanish ophthalmologists about the effectiveness of the available vaccines against HZ. A Google Forms questionnaire was created and used as the survey platform for this study. It was an anonymous online survey of 16 questions, which was shared among Spanish ophthalmologists in-training and consultants from 27 April 2022 to 25 May 2022. The survey was completed by a total of 206 ophthalmologists of all subspecialties. We obtained responses from 17 of the 19 regions of Spain. Fifty-five percent of the respondents agreed that HZ is a frequent cause of vision loss. However, 27% of the professionals were unaware of the existence of vaccines against HZ and 71% of them did not know in which cases it could be indicated. Only nine ophthalmologists (4%) had ever suggested vaccination against HZ to their patients. Despite this, 93% considered it important to recommend vaccination against HZ if it proved to be safe and effective. Considering the sequelae, complications, and the existence of safe and effective vaccines against HZ, vaccination of the target population could be considered an important public health measure. We are convinced that it is time for ophthalmologists to take an active role in HZO prevention.

Septo-optic dysplasia (SOD) or Morsier syndrome is a rare congenital malformation of infantile neurodevelopment with systemic anatomical and functional involvement. It is characterized by optic nerve hypoplasia, midline brain malformation, and hypothalamic-pituitary axis hypoplasia. The spectrum of clinical manifestations is very wide, from ophthalmological problems to endocrinological disorders that determine the severity and prognosis of these patients. The diagnosis is fundamentally clinical, based on an anamnesis and systematic clinical examination, supported by complementary tests for the study of hormonal deficits and imaging tests that objectify structural malformations. SOD has no cure; however, close follow-up focused on improving comorbidities through hormone replacement, neuropsychological support, and visual correction is necessary to improve the patient’s quality of life. Its low incidence and the breadth of forms of presentation require the knowledge and multidisciplinary approach of specialists in Pediatrics, Neurology, Endocrinology and Ophthalmology, among others. We present a descriptive case of this disease and its management.

Retinitis Pigmentosa (RP) and Idiopathic Intracranial Hypertension (IIH) are two different pathologies that can have a very similar presentation (headache and loss of visión). The differential diagnosis of both is essential due to their different management and prognosis. We present the case of a young woman with a 2-year history of headache, visual loss and buzzing in the head. In the fundus of both eyes, typical findings of RP (bone spicules in the middle retina and arteriolar thinning) and IIH (bilateral papilledema) stand out, although the latter is also described in cases of RP. After a complete study in Ophthalmology and Neurology, the diagnosis of both pathologies is reached, with symptomatic and visual improvement after starting treatment to reduce intracranial pressure. The coincidence of both entities is extremely infrequent in the same patient, a high index of suspicion is required due to their clinical similarities and a multidisciplinary collaboration for their diagnosis.

Background: There are currently two authorized vaccines against Varicella Zoster Virus (VZV) that have proved to be safe and effective in the prevention of VHZ. Ophthalmologists commonly treat Herpes Zoster Ophthalmicus (HZO) and its complications. Therefore, ophthalmologists are indeed in a privileged position to advocate for VZV vaccination. Our aim was to find out the current knowledge among Spanish ophthalmologists regarding the effectiveness of the available vaccines against VZV.Methods: A Google-Forms questionnaire was created and used as the survey platform for this study. It was an anonymous online survey of 16 questions, which was shared among Spanish ophthalmologists-in-training and consultants from April 27th, 2022, to May 25th, 2022. Results: The survey was completed by a total of 206 ophthalmology professionals from all subspecialties. We obtained responses from 17 of the 19 regions of Spain. Fifty-five percent of the respondents agreed that VZV is a frequent cause of vision loss. However, 27% of the professionals were unaware of the existence of vaccines against VZV and 71% of them did not know in which cases it could be indicated. Only 9 ophthalmologists (4%) had ever indicated vaccination against VZV in their patients. Despite this, 93% considered important to recommend vaccination against VZV in case it proved to be safe and effective. Conclusions: Considering the sequelae, complications, and the existence of safe and effective vaccines against VZV, vaccination of the target population could be considered an important public health measure. The time has come for ophthalmologists to take an active role in HZO prevention.